WO2007142230A1 - 脂質代謝改善剤 - Google Patents
脂質代謝改善剤 Download PDFInfo
- Publication number
- WO2007142230A1 WO2007142230A1 PCT/JP2007/061361 JP2007061361W WO2007142230A1 WO 2007142230 A1 WO2007142230 A1 WO 2007142230A1 JP 2007061361 W JP2007061361 W JP 2007061361W WO 2007142230 A1 WO2007142230 A1 WO 2007142230A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- casein
- group
- lipid metabolism
- food
- fat
- Prior art date
Links
- 239000005018 casein Substances 0.000 claims abstract description 105
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 78
- 235000013305 food Nutrition 0.000 claims abstract description 64
- 150000002632 lipids Chemical class 0.000 claims abstract description 56
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 54
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 48
- 239000008280 blood Substances 0.000 claims abstract description 48
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 230000001603 reducing effect Effects 0.000 claims abstract description 16
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 34
- 235000019786 weight gain Nutrition 0.000 claims description 30
- 230000004584 weight gain Effects 0.000 claims description 29
- 239000003638 chemical reducing agent Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 235000021240 caseins Nutrition 0.000 claims description 25
- 235000005911 diet Nutrition 0.000 claims description 23
- 230000009467 reduction Effects 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000001629 suppression Effects 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 30
- 230000037396 body weight Effects 0.000 abstract description 26
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 58
- 230000000694 effects Effects 0.000 description 48
- 239000003925 fat Substances 0.000 description 37
- 235000019197 fats Nutrition 0.000 description 36
- 235000013336 milk Nutrition 0.000 description 33
- 239000008267 milk Substances 0.000 description 33
- 210000004080 milk Anatomy 0.000 description 33
- 239000000523 sample Substances 0.000 description 27
- 102000011632 Caseins Human genes 0.000 description 23
- 108010076119 Caseins Proteins 0.000 description 23
- 230000037213 diet Effects 0.000 description 20
- 208000008589 Obesity Diseases 0.000 description 19
- 210000001596 intra-abdominal fat Anatomy 0.000 description 19
- 235000020824 obesity Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 235000009200 high fat diet Nutrition 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 210000004003 subcutaneous fat Anatomy 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000036541 health Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 101150118197 CSN1S1 gene Proteins 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- -1 ion chloride Chemical class 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000013068 control sample Substances 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000012045 salad Nutrition 0.000 description 3
- 235000013547 stew Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 235000021247 β-casein Nutrition 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000001916 dieting Nutrition 0.000 description 2
- 230000037228 dieting effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Obesity is known to be accompanied by many risk factors such as abnormal lipid metabolism, high blood pressure, impaired glucose tolerance, and the like. As the visceral fat accumulation increases, total cholesterol and neutral fat increase, and HDL (high density lipoprotein) decreases. In addition, qualitative abnormalities of LDL (low density lipoprotein) occur, and the accumulation of visceral fat affects the lipid metabolism quantitatively and qualitatively. In obese individuals, abnormalities of lipid metabolism are frequently observed, and in particular, an increase in the amount of total cholesterol in the blood and an increase in blood neutral fat are observed.
- Non-Patent Document 1 Kawasaki et al. Have a milk intake group that ingests 200 ml of milk per day and a control that does not force the intake of milk when dieting and exercising for 4 months. Observation was divided into groups. As a result, there was no significant difference between the control group and the milk intake group in terms of weight loss before and after the four-month diet, but the body fat percentage of the trunk was higher in the milk intake group than in the control group. There is a clear decrease in comparison, and it has been reported that this effect may be due to calcium and vitamin D contained in milk.
- Patent Document 2 Japanese Translation of Special Publication 2006—501299
- Non-Patent Document 2 Journal of the American College of Nutrition, 19th, 2000, pp. 754-760
- Non-Patent Document 3 F 'E' 'S' 1 'B' Journal (FASEB Journal), 14th, 2
- the conventional technology as described above is not always effective enough, has high safety, has an excellent lipid metabolism improvement effect, and is effective for symptoms of lifestyle-related diseases caused by obesity. There is a need to develop new drugs and foods and drinks.
- the inventors of the present invention have made extensive studies on active ingredients that are inexpensive and safe and can improve lipid metabolism in the body. Specifically, we focused on milk ingredients, which are naturally derived ingredients with abundant dietary experience, and as a result of searching for substances that have an excellent lipid metabolism improving effect that has never been seen before, s-casein is one of the strong zeins. It was found that it has a remarkable lipid metabolism improving effect compared to ⁇ -casein, ⁇ -casein and the like, which are the casein fractions of the present invention, and the present invention has been completed.
- the present invention relates to a lipid metabolism improving agent containing ct s-casein as an active ingredient.
- the present invention also relates to the use of s-casein for producing the lipid metabolism improving agent, the weight gain inhibitor, the body fat reducing agent, or the blood lipid reducing agent.
- the present invention also relates to a method for improving lipid metabolism in mammals by administering the lipid metabolism improving agent.
- the present invention also relates to a method for suppressing weight gain of mammals by administering the weight gain inhibitor.
- the present invention also relates to a method for reducing body fat in mammals by administering the body fat reducing agent.
- the present invention also relates to a method for reducing blood lipids in mammals by administering the blood lipid reducing agent.
- the food and drink may be in the form of health food, functional food, special purpose food, nutritional functional food, or food for specified health use.
- the present invention also relates to a feed for improving lipid metabolism containing as-casein as an active ingredient.
- lipid metabolism improving agent having high safety and excellent lipid metabolism improving effect can be obtained.
- the effects obtained by the lipid metabolism improving agent of the present invention are as follows.
- the lipid metabolism-improving agent of the present invention has an action of promoting metabolism of subcutaneous fat and visceral fat that is excessively consumed by diet and accumulated in the living body. This suppresses weight gain, In addition, a significant effect is obtained in reducing body fat including visceral fat. Therefore, it is useful for the prevention and improvement of obesity.
- the lipid metabolism-improving agent of the present invention can be taken daily for a long period of time without worrying about side effects that are highly safe for humans and animals. Therefore, it is suitable for the prevention and / or treatment of lifestyle-related diseases such as hyperlipidemia, hypertension and diabetes that are also caused by moonlight.
- a lipid metabolism improving agent Since s-casein, which is an active ingredient of the present invention, can stably produce a large amount of raw material such as milk which is relatively inexpensive as a biomaterial, a lipid metabolism improving agent should be provided at a low cost. Is possible. It is also possible to provide a lipid metabolism improving agent as a form of food or drink or feed. For this reason, also from the viewpoint of cost burden, it is possible to provide a lipid metabolism improving agent that can be ingested continuously for a long period of time and a food or drink or feed containing the lipid metabolism improving agent. .
- security is obtained.
- security is obtained.
- FIG. 3 is a graph showing the time course of body fat weight, which is a combination of visceral fat weight and subcutaneous fat weight in a test example.
- FIG. 4 is a graph showing changes in body fat percentage over time in test examples.
- FIG. 5 is a graph showing the relationship between the dose of a s-casein and the ratio of the weight of intraperitoneal fat per body weight in a test example.
- FIG. 6 is a graph showing the relationship between as-casein dose and blood lipids in test examples.
- FIG. 7 is a graph showing the relationship between as-casein dose and blood free fatty acid concentration in Test Examples.
- the lipid metabolism improving agent of the present invention can be suitably used as a weight gain inhibitor, a body fat reducing agent, and / or a blood lipid reducing agent.
- a blood lipid reducing agent can be provided.
- a method for improving lipid metabolism in mammals, a method for suppressing weight gain, a method for reducing body fat, or a method for reducing blood lipids by administering these drugs is provided.
- the “mammal” includes humans and livestock animals (eg, horses, dogs, cats, rabbits, rabbits, hedges, goats, etc.).
- the effect of the present invention is to metabolize excess lipid accumulated in the body, and has almost no effect of reducing the required lipid.
- the “treatment” in the present invention includes an effect of alleviating (improving) symptoms and an effect of treating a disease.
- the therapeutic effect obtained by the present invention is preferably the effect of introducing into remission and the effect of maintaining its state. According to the present invention, as a result of daily administration or ingestion of as-casein, which is an active ingredient, almost no side effects occur, and the lipid metabolism improving effect is exhibited.
- As-casein used in the present invention is obtained from raw materials such as milk, for example, ion chloride. It can be industrially produced according to a conventional method such as a matography method. For example, J. Dairy Researc h, 59th, 1992, 551-
- s_casein for example, manufactured by Sigma
- recombinant s_casein can be used as desired.
- the s-casein is preferably derived from mammalian milk.
- s-casein derived from milk such as cows, sheep and goats, which are traditionally used for food and drink, is preferable. These have been used for human consumption during historical years, and are therefore secured to a very high level of safety for humans. Among them, it is preferable to use milk s-casein.
- the administration method of the lipid metabolism improving agent, weight gain inhibitor, body fat reducing agent, and blood lipid reducing agent of the present invention is not particularly limited.
- oral administration or parenteral administration such as enteral administration may be used.
- lipid metabolism-improving agent of the present invention As -casein, which is an active ingredient in the lipid metabolism-improving agent of the present invention, is contained in foods such as milk and is taken on a daily basis. It does not exhibit toxicity and is taken continuously for a long period of time. However, there are almost no side effects. That is, the safety when ingested is extremely high, and is particularly suitable for oral administration or enteral administration.
- the lipid metabolism improving agent of the present invention may be an agent consisting of s-casein alone or an agent consisting of a composition containing other components. In any case, it is preferable that it is formulated into a dosage form according to the application.
- the weight gain inhibitor, body fat reducing agent, and blood lipid reducing agent of the present invention may be an agent consisting of the above lipid metabolism improving agent alone or an agent consisting of a composition containing other components.
- the dosage forms of agents, weight gain inhibitors, body fat reducing agents, and blood lipid reducing agents are not particularly limited.
- known oral dosage forms such as tablets, capsules, troches, syrups, granules, powders, emulsions, sprays and the like can be used.
- the dose of s-casein which is an active ingredient of the lipid metabolism-improving agent of the present invention, depends on the dosage form, 80mg / mg in order to effectively exert one or more selected from lipid metabolism improving effect, weight gain inhibiting effect, body fat reducing effect, and blood lipid reducing effect, depending on the condition, age, weight, etc. It is preferable to have a dosage of kg body weight / day or more.
- As-casein is highly safe, so the upper limit of the dose is not limited, but the lipid metabolism improvement effect according to the present invention can be fully enjoyed especially when an amount of about 320 mg / kg body weight / day is administered. .
- the upper limit of the dose is preferably 320 mg / kg body weight / day or less.
- the lipid metabolism improving agent, weight gain inhibitor, body fat reducing agent, and blood lipid reducing agent of the present invention are formulated so that the daily dose of s-casein falls within the above range. It is also preferable to administer the s-casein so that the daily dose is within the above range.
- Formulation can be performed by a known method, for example, by appropriately using as s-casein any additive such as a pharmaceutically acceptable excipient.
- additives such as excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, and solvents for injections can be used.
- the content of as-casein in the composition is not particularly limited, but is usually 0. ! ⁇ 90 mass%, preferably 0.5-40 mass%, more preferably 1-20 mass%.
- the content of the lipid metabolism improving agent in the composition is particularly The amount is not limited, but is usually 0.5 :! to 90% by mass, preferably 0.5 to 40% by mass, more preferably 1 to 20% by mass.
- excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbit; starch derivatives such as corn starch, potato starch, chicken starch, dextrin, and carboxymethyl starch; Cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium; gum arabic; dextran; pullulan
- Silicates such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium magnesium metasilicate Derivatives; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; sulfate derivatives such as calcium sulfate and the like.
- binder examples include gelatin, polyvinyl pyrrolidone, maglogol and the like in addition to the above excipients.
- lubricants include: talc; stearic acid; stearic acid metal salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as bee gum and gallow; boric acid; glycol; carboxyl such as fumaric acid and adipic acid Acids; Sodium carboxylic acid salts such as sodium benzoate; Sulfates such as sodium sulfate; Leucine; Lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; Silicates such as anhydrous silicic acid and silicic acid hydrate; Starch derivatives Etc.
- Examples of the solvent for injection include water, ethanol, glycerin and the like.
- the food or drink containing the lipid metabolism improving agent of the present invention is a food or drink containing cts-casein as an active ingredient and having an effect of improving lipid metabolism.
- the food and drink can be used for various purposes that utilize the effect of improving lipid metabolism.
- a particularly suitable use is one or more selected from suppression of weight gain, reduction of body fat, and reduction of blood lipids.
- Such foods and beverages include, for example, s-casein, saccharides such as dextrin and starch; proteins such as gelatin, soybean protein, and corn protein; amino acids such as alanine, gnoretamine, and iso-icin; cellulose, gum arabic, etc.
- Polysaccharides Can be produced by appropriately blending oils such as soybean oil and medium chain fatty acid triglycerides.
- the form of food and drink is preferably a form that can be taken on a daily basis.
- soft drinks, carbonated drinks, nutrient drinks, fruit drinks, lactic acid drinks and other drinks including concentrated concentrates and conditioning powders of these drinks
- ice cream, ice sherbet, frozen ice cream, etc . buckwheat , Udon, Harusame, Gyoza skin, Pomegranate skin, Chinese rice bowl, Instant rice cake, etc.
- Sweets such as kamaboko, ham, sausage, etc .
- Livestock processed foods Processed milk, dairy products such as fermented milk; Salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing, etc.
- Seasonings such as sauces and sauces; soups, stews, salads, prepared dishes, pickles, bread; enteral nutrition; functional foods, etc. That.
- Such feed includes, for example, as-casein, grains such as corn, wheat, barley, rye, and my mouth; vegetable oils such as soybean oil meal, rapeseed oil meal, coconut oil meal, and Amani oil meal; bran, wheat straw, rice bran Potatoes such as defatted rice bran; corns such as corn darten meal and corn jam meal; animal feeds such as fish meal, skim milk powder, whey, yellow grease and tallow; yeasts such as tral yeast and brewer's yeast Mineral substances such as tricalcium phosphate, calcium carbonate, etc. Feed; fats and oils; simple amino acids; sugars and the like.
- the form of the feed is preferably a form that can be fed on a daily basis.
- Specific examples include pet food, livestock feed, and fish feed.
- the lipid metabolism improving agent of the present invention may be used alone, but may be used in combination with other pharmaceutical compositions, foods and drinks, or feeds that are effective in improving lipid metabolism.
- the combined use can enhance effects such as weight gain suppression, body fat reduction, blood lipid reduction and the like.
- the pharmaceutical composition, food or drink, or feed to be used may be contained as an active ingredient in the pharmaceutical composition, food or drink, or feed according to the present invention, or the pharmaceutical composition, food or drink, or feed of the present invention. May be combined and commercialized as separate drugs, foods and drinks, etc.
- the food and drink according to the present invention include a food and drink whose use for improving lipid metabolism is displayed, such as "a food and drink having an effect of improving lipid metabolism, displayed as lipid metabolism improving", " It is preferable to sell as “a food or drink containing s-casein” labeled as “improving lipid metabolism” or “a food or drink containing s-casein labeled as“ preventing body fat accumulation ”.
- the wording used for the above display is not limited to the words “for improving lipid metabolism” or “for preventing body fat accumulation”, for example. Needless to say, any word that expresses the effect of improving metabolism is included in the scope of the present invention. As such a wording, for example, a display based on various uses for causing a consumer to recognize a lipid metabolism improving effect and / or an improving effect is also possible.
- the indications for the prevention and / or improvement of lifestyle-related diseases are used for the prevention and / or improvement of lifestyle-related diseases such as hyperlipidemia, hypertension and diabetes caused by obesity. It is also possible to sell it as a food or drink.
- the act of "display” includes all acts for informing consumers of the use, and if it is a display that can recall the use, Regardless of the purpose of display, the content of display, the object to be displayed, the medium, etc., all fall under the “display” act of the present invention. However, it is preferable to display it in an expression that allows the consumer to directly recognize the use. Specifically, an act of describing the above-mentioned use in a product relating to food or drink or a packaging of the product can be cited as a display act, and further, a product describing the above-mentioned use in the packaging of the product or product is transferred and delivered. Displayed for transfer or delivery, importing, advertising related to products, price list or transaction documents Exhibit or distribute, or describe the above-mentioned use in information containing these information and provide them by electromagnetic (Internet etc.) methods.
- the displayed content includes a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government and is performed in a manner based on such approval). It is preferable to attach such display content to packaging materials, containers, catalogs, pamphlets, advertising materials at sales sites such as POP, and other documents.
- indications as health food, functional food, enteral nutrition food, special purpose food, health functional food, food for specified health, functional nutrition food, quasi drug, and the like can be exemplified.
- the labeling approved by the Ministry of Health, Labor and Welfare for example, the labeling approved under the food system for specified health use and similar systems can be exemplified. Examples of the latter can include indications as foods for specified health use, indications as conditional foods for specified health use, indications that affect the structure and function of the body, indications for reducing disease risk, etc.
- the indications for foods for specified health stipulated in the Enforcement Regulations of the Health Promotion Act (April 30, 2003 Ministry of Health, Labor and Welfare Ordinance No. 86) Similar displays can be listed as typical examples.
- Example 1 (Production of as-casein) First, a strong anion exchanger (manufactured by Falmacia) equilibrated with 0 ⁇ 02 ⁇ Tris-HCl buffer ( ⁇ X8 ⁇ 0) containing 4M urea and 6.5 x 10 X dithiothreitol 2. 4L Prepared. After removing the buffer solution from this strong anion exchanger, 90g sodium caseinate (manufactured by Morinaga Milk Industry Co., Ltd.) dissolved in 3L buffer solution was added, and the ion exchanger was slowly stirred for about 30 minutes. The supernatant was separated. As a result, a strong anion exchanger adsorbed with casein (six, ⁇ and / 3 casein) is obtained.
- Example 2 (Production of tablet-like lipid metabolism improving agent)
- Whey protein hydrolyzate (Morinaga Milk Industry Co., Ltd.) 10 kg, dextrin (Showa Sangyo Co., Ltd.) 36 kg, and a small amount of water-soluble vitamins and minerals dissolved in 200 kg water to prepare the aqueous phase in the tank Made.
- soybean salad oil (manufactured by Taiyo Yushi Co., Ltd.) 3 kg
- palm oil (manufactured by Taiyo Yushi Co., Ltd.) 8.5 kg
- safflower oil (manufactured by Taiyo Yushi Co., Ltd.) 2.5 kg
- lecithin (manufactured by Ajinomoto Co., Inc.) 0.2 kg
- Fatty acid monoglyceride manufactured by Kao Corporation 0.2 kg and a small amount of fat-soluble vitamin were mixed and dissolved to prepare an oil phase.
- the oil phase was added to the aqueous phase in the tank, and the mixture was stirred and mixed, then heated to 70 ° C., and further homogenized with a homogenizer at a pressure of 14.7 MPa. Then, after sterilizing at 90 ° C. for 10 minutes, it was concentrated and spray-dried to prepare about 59 kg of intermediate product powder.
- sucrose (Hokuren) 6.8 kg, amino acid mixed powder (Ajinomoto Co.) 1 67 g, and s-casein lkg obtained by the method of Example 1 were added, It was mixed uniformly to produce about 56 kg of enteral nutritional powder containing s-casein.
- Example 4 Manufacture of stew containing s-casein having lipid metabolism improving effect 1/2 onion cut into lcm squares was fried in 7 g of butter, and 2/3 of thin flour And then fried. Add 200ml water and 1Z3 teaspoon bouillon to melt, add 1 potato cut into lcm squares, add 15g loin ham lump, mix beans can (1/3 can), and simmer. When the sweet potatoes become soft, add 15g of as-casein, prepared in the same way as in Example 1, and boil it, adjust the taste with salt and pepper, and improve lipid metabolism. A stew containing as-casein was prepared.
- Example 5 (Production of orange milk jelly containing a s-casein having an effect of improving lipid metabolism)
- Tables 4 to 6 show the average values of subcutaneous fat weight, visceral (intraperitoneal) fat weight, and lean body mass in the animal abdomen of each group after 8 weeks. Also, body fat after 8 weeks Table 7 shows the average values of fat percentage.
- the “PC group to which the control sample was administered with the high fat diet” had a significantly higher adipose tissue weight, and on the contrary, the lean body mass was low. It turned out to be decreasing. There was a significant difference in both visceral fat and subcutaneous fat between the NC group and the PC group, and it was clear that the cause of weight gain in the PC group observed in Test Example 1 was due to an increase in fat weight in the body. It was.
- FIG. 1 is a graph showing changes in visceral fat weight over time.
- the 2nd week force was no longer observed as much as the PC group (NC group: 1.6 g, PC group: 2. lg), but in the s group, until the 2nd week, S group: 2.5 g, j3 group: 2. lg, ⁇ group: 2.7 g, CsNa group: 2.5 g).
- the weight S was less than that in the NC group (NC group: 1.7 g, ⁇ 3 group: 0.9 g); It was revealed that the weight recovered to almost the same weight as the NC group (NC group: 2. lg, as group: 2.9 g).
- FIG. 2 is a graph showing changes in subcutaneous fat weight over time.
- the increase in subcutaneous fat weight increased significantly from the 2nd to 4th week, as in the PC group (PC group: 1.6 g, as group: 2. Og), but then the trend of increase gradually slowed.
- the 8th week it decreased rapidly (PC group: 2 • 8g, as group: 1.2g).
- Fig. 3 is a graph showing changes in body fat weight over time, which is a combination of visceral fat weight and subcutaneous fat weight.
- the trend of increasing body fat weight was confirmed up to the 2nd week as in the PC group and other casein groups (PC group: 3.3 g, as group: 4.2 g, group: 3. lg, / group: 4. lg, CsNa group: 4.9 g)
- the curve of increase became gentle, it turned to decrease, and after decreasing to the same level as NC group at 6 weeks, (6 weeks, NC group: 2.6 g, s group: 3.0 g), and again increased to the same level as the NC group, confirming a tendency to rebound (8 weeks, NC group: 3. 2g, as group: 4. lg).
- each group was divided into 6 groups of 8 animals so that their body weights were almost the same, and each group was given free access to food and water.
- samples were administered at 0.5 ml / mouse using a sonde at a pace of once a day for 5 days of the week.
- the types of food and samples in each group are the same as in Test Example 1.
- each group was divided into 6 groups of 8 animals so that their body weights were almost the same, and each group was given free access to food and water.
- the sample was administered 0.5 mlZ at a rate of once a day using a sonde for 5 days of the week. Feeding in each group
- the materials and sample types are the same as in Test Example 1.
- Serum lipids were analyzed using an automatic clinical chemistry analyzer (ARKRAY: Spotchem), total cholesterol (T-Cho, unit: mg / dL) and Neutral fat (TG, unit: mg / dL) was measured.
- ARKRAY Spotchem
- T-Cho total cholesterol
- TG Neutral fat
- a S —Casein improves the lipid metabolism in the body.
- animals under high-fat diet were administered with s-casein solution prepared at different concentrations, and the internal organs per body weight Fat weight was measured.
- Control distilled water for injection
- a sCs sample Hi s-casein (Sigma) dissolved in distilled water for injection (Otsuka Pharmaceutical) Thus, the protein concentration was adjusted to 0.5 mg / ml, 5 mg / ml, and 20 mg / ml.
- each group was divided into 6 groups of 8 animals so that their body weights were almost the same, and each group was given free access to food and water.
- 0.5 mlZ of the sample was administered using a sonde at a daily pace.
- the body weight was measured after the end of the test period, and then dissected and the intraperitoneal fat weight was measured.
- the study period was 12 weeks after grouping. About each group, it is as follows.
- Group 2 0.5 mg / ml 's-casein administration (Hi-ichi 0.5 group)
- Group 4 20 mg / ml 'a s-casein administration ( ⁇ -20 group)
- a s-casein solution prepared at different concentrations was administered to an animal fed with a high fat diet, and the amount of lipid contained in the blood was measured.
- each group was divided into 6 groups of 8 animals so that their body weights were almost the same, and each group was given free access to food and water.
- the sample was administered 0.5 mlZ at a rate of once a day using a sonde for 5 days of the week.
- Each group was dissected and blood collected at the end of the test period (12 weeks). From the collected blood, serum was separated with a serum separation tube (manufactured by Cosmo Bio) containing a coagulation promoting type separation agent. T_Cho and TG in the blood were measured using an automatic clinical chemistry analyzer (Arkray, Inc .: Spotchem (registered commercial method)).
- free fatty acids in serum were measured with NEFA-C Test Toko (manufactured by Wako Pure Chemical Industries, Ltd.). About each group, it is as follows.
- Control administration (control group)
- Group 2 Administration of 0.5 mg / ml 'a s-casein ( ⁇ -0.5 group)
- Fig. 7 shows the measurement results of blood free fatty acid concentration.
- the control group was 1.66 61 mEq / l, whereas a ⁇ 0.5: 0. 999 mEq / l, ⁇ — 5: 1. 305 mEq / l, H1 20: 1. 312 mEqZl. It was confirmed that the concentration of free fatty acid in the blood was significantly decreased in all the groups administered with s-casein compared to the control group.
- lipid metabolism improving agent capable of (induction and maintenance of remission) is obtained.
- as-casein which is an active ingredient in the present invention, can be produced in large quantities from raw materials such as milk, and therefore it is possible to provide lipid metabolism improving agents and foods and drinks and feeds containing them at low cost. is there.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008520585A JP4394155B2 (ja) | 2006-06-09 | 2007-06-05 | 脂質代謝改善剤 |
CN2007800106979A CN101410131B (zh) | 2006-06-09 | 2007-06-05 | 脂质代谢改善剂 |
US12/281,485 US8921310B2 (en) | 2006-06-09 | 2007-06-05 | Method for accelerating mammalian body fat metabolism |
EP07744713.4A EP2030629B1 (en) | 2006-06-09 | 2007-06-05 | Alpha-s-casein as lipid-metabolism-improving agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-161076 | 2006-06-09 | ||
JP2006161076 | 2006-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007142230A1 true WO2007142230A1 (ja) | 2007-12-13 |
Family
ID=38801481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/061361 WO2007142230A1 (ja) | 2006-06-09 | 2007-06-05 | 脂質代謝改善剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8921310B2 (ja) |
EP (1) | EP2030629B1 (ja) |
JP (2) | JP4394155B2 (ja) |
CN (1) | CN101410131B (ja) |
WO (1) | WO2007142230A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011063552A (ja) * | 2009-09-18 | 2011-03-31 | Hokkaido Univ | 身体活動促進剤 |
US20110165138A1 (en) * | 2008-06-26 | 2011-07-07 | Healthlinx Limited | Protocols for treating and preventing obesity and complications arising therefrom |
JP2015096072A (ja) * | 2014-12-09 | 2015-05-21 | 国立大学法人北海道大学 | 身体活動促進剤 |
WO2019058609A1 (ja) | 2017-09-19 | 2019-03-28 | 森永乳業株式会社 | エネルギー消費促進用組成物 |
US20190224260A1 (en) * | 2016-07-13 | 2019-07-25 | J-Oil Mills, Inc. | Metabolic Syndrome Inhibitor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2512269B1 (en) * | 2009-12-18 | 2016-07-13 | Stokely-Van Camp, Inc. | Protein recovery beverage |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05146258A (ja) * | 1991-11-27 | 1993-06-15 | Snow Brand Milk Prod Co Ltd | カゼインをα−カゼインとβ−カゼインとに分画する方法 |
JPH0640936A (ja) * | 1992-07-16 | 1994-02-15 | Sumiaki Tsuru | 高脂血症の予防及び治療剤 |
JPH06211690A (ja) | 1993-01-21 | 1994-08-02 | Kanebo Ltd | 血中脂質抑制用摂食物 |
JP2000287656A (ja) * | 1999-04-09 | 2000-10-17 | Toyo Seikan Kaisha Ltd | 容器入り乳飲料の高温保存期間を推定する方法 |
JP2003523368A (ja) * | 2000-02-23 | 2003-08-05 | パシフィックヘルス ラボラトリーズ インコーポレイテッド | 飽満感を高め、持続させるための栄養摂取介入組成物 |
WO2004050118A1 (ja) * | 2002-11-29 | 2004-06-17 | Morinaga Milk Industry Co., Ltd. | システインプロテアーゼ阻害剤 |
JP2006501299A (ja) | 2002-10-04 | 2006-01-12 | エイツー・コーポレーション・リミテッド | β−カゼインA2、およびβ−カゼインA2を含有する栄養補助食品の治療での使用 |
JP2006507217A (ja) | 2002-03-01 | 2006-03-02 | グランビア ニュートリショナルズ (アイルランド) リミテッド | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19510765A1 (de) | 1995-03-24 | 1996-09-26 | Alexander Buehlbaecker | Verfahren zur Herstellung von Frühgeborenen-, Säuglings- und Diätnahrung |
US7666996B2 (en) * | 2000-03-01 | 2010-02-23 | Peptera Pharmaceuticals Ltd | Casein derived peptides and uses thereof |
GB0116509D0 (en) * | 2001-07-06 | 2001-08-29 | Hannah Res Inst The | Methods of extracting casein fractions from milk and caseinates and production of novel products |
CA2458924A1 (en) | 2001-08-30 | 2003-03-06 | Chay 13 Medical Research Group N.V. | Casein derived peptides and uses thereof in therapy |
CN1691961A (zh) * | 2002-11-29 | 2005-11-02 | 森永乳业株式会社 | 半胱氨酸蛋白酶抑制剂 |
-
2007
- 2007-06-05 US US12/281,485 patent/US8921310B2/en not_active Expired - Fee Related
- 2007-06-05 JP JP2008520585A patent/JP4394155B2/ja not_active Expired - Fee Related
- 2007-06-05 CN CN2007800106979A patent/CN101410131B/zh active Active
- 2007-06-05 WO PCT/JP2007/061361 patent/WO2007142230A1/ja active Application Filing
- 2007-06-05 EP EP07744713.4A patent/EP2030629B1/en active Active
-
2009
- 2009-07-17 JP JP2009169069A patent/JP2009256366A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05146258A (ja) * | 1991-11-27 | 1993-06-15 | Snow Brand Milk Prod Co Ltd | カゼインをα−カゼインとβ−カゼインとに分画する方法 |
JPH0640936A (ja) * | 1992-07-16 | 1994-02-15 | Sumiaki Tsuru | 高脂血症の予防及び治療剤 |
JPH06211690A (ja) | 1993-01-21 | 1994-08-02 | Kanebo Ltd | 血中脂質抑制用摂食物 |
JP2000287656A (ja) * | 1999-04-09 | 2000-10-17 | Toyo Seikan Kaisha Ltd | 容器入り乳飲料の高温保存期間を推定する方法 |
JP2003523368A (ja) * | 2000-02-23 | 2003-08-05 | パシフィックヘルス ラボラトリーズ インコーポレイテッド | 飽満感を高め、持続させるための栄養摂取介入組成物 |
JP2006507217A (ja) | 2002-03-01 | 2006-03-02 | グランビア ニュートリショナルズ (アイルランド) リミテッド | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
JP2006501299A (ja) | 2002-10-04 | 2006-01-12 | エイツー・コーポレーション・リミテッド | β−カゼインA2、およびβ−カゼインA2を含有する栄養補助食品の治療での使用 |
WO2004050118A1 (ja) * | 2002-11-29 | 2004-06-17 | Morinaga Milk Industry Co., Ltd. | システインプロテアーゼ阻害剤 |
Non-Patent Citations (7)
Title |
---|
"Proceedings of the annual meeting", JOURNAL OF JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE, 2006, pages 343 |
FASEB JOURNAL, vol. 14, 2000, pages 1132 - 1138 |
JOURNAL OF DAIRY RESEARCH, vol. 59, 1992, pages 551 - 556 |
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, vol. 19, 2000, pages 754 - 760 |
KAWASAKI I. ET AL.: "Genryochu no Jakunen Josei ni oite Gyunyu oyobi Vitamin-D no Sesshu ga Taishiboryo, Kinryo ni Donoyona Eikyo o Ataeruka", DAI 60 KAI THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE TAIKAI KOEN YOSHISHU, 1 April 2006 (2006-04-01), pages 343, XP003020194 * |
OBESITY RESEARCH, vol. 10, 2002, pages 956 - 963 |
ORDINANCE NO. 86 OF THE MINISTRY OF HEALTH, LABOUR AND WELFARE IN JAPAN, 30 April 2003 (2003-04-30) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110165138A1 (en) * | 2008-06-26 | 2011-07-07 | Healthlinx Limited | Protocols for treating and preventing obesity and complications arising therefrom |
JP2011063552A (ja) * | 2009-09-18 | 2011-03-31 | Hokkaido Univ | 身体活動促進剤 |
JP2015096072A (ja) * | 2014-12-09 | 2015-05-21 | 国立大学法人北海道大学 | 身体活動促進剤 |
US20190224260A1 (en) * | 2016-07-13 | 2019-07-25 | J-Oil Mills, Inc. | Metabolic Syndrome Inhibitor |
WO2019058609A1 (ja) | 2017-09-19 | 2019-03-28 | 森永乳業株式会社 | エネルギー消費促進用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007142230A1 (ja) | 2009-10-29 |
EP2030629B1 (en) | 2014-04-30 |
US8921310B2 (en) | 2014-12-30 |
JP2009256366A (ja) | 2009-11-05 |
US20090012001A1 (en) | 2009-01-08 |
EP2030629A4 (en) | 2012-06-27 |
EP2030629A1 (en) | 2009-03-04 |
JP4394155B2 (ja) | 2010-01-06 |
CN101410131A (zh) | 2009-04-15 |
CN101410131B (zh) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5715117B2 (ja) | 摂食障害治療剤 | |
KR20080043867A (ko) | 글루카곤양 펩티드-1 분비 촉진제, 글루카곤양 펩티드-1분비 촉진용 음식품, 식후 혈당값 상승 억제제 및 식후혈당값 상승 억제용 음식품 | |
JP4394155B2 (ja) | 脂質代謝改善剤 | |
JP4979596B2 (ja) | 腸疾患のための医薬組成物、飲食品、又は飼料 | |
JP2010018522A (ja) | アディポネクチン産生促進剤 | |
JP2017031105A (ja) | 食後血糖値の上昇抑制を促進させる剤 | |
JP7358239B2 (ja) | エネルギー消費促進用組成物 | |
JP6369990B2 (ja) | 筋萎縮抑制剤及び筋萎縮抑制用飲食品 | |
JP2007031403A (ja) | 乳酸産生抑制剤 | |
JP5087297B2 (ja) | インターロイキン−11産生促進剤 | |
JP2021024838A (ja) | 子における脳由来神経栄養因子の産生を促進させる組成物 | |
JP7369568B2 (ja) | アルコール代謝促進用組成物 | |
WO2023190809A1 (ja) | コルチゾール産生抑制用組成物 | |
JP2020132621A (ja) | 皮膚ガス放散調節用組成物 | |
CN112040972A (zh) | 用于降低血压和/或用于减少中性脂肪的组合物 | |
JP6797966B2 (ja) | 胃内酸性プロテアーゼ酵素活性阻害剤、ラクトフェリン組成物の製造方法、及びラクトフェリン組成物 | |
JP7309436B2 (ja) | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7299744B2 (ja) | 血中尿酸値低減用組成物、及び高尿酸血症予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP5022060B2 (ja) | インターロイキン−10産生促進剤 | |
JP2017165661A (ja) | 糖質代謝改善剤 | |
JP2023025199A (ja) | 血圧降下用及び/又は中性脂肪低減用の組成物 | |
JP5950395B2 (ja) | 卵白アルブミン分解物を含有する脂質代謝改善剤 | |
JP4717413B2 (ja) | 脂質代謝改善用組成物 | |
WO2022172523A1 (ja) | プラズマサイトイド樹状細胞活性化用組成物 | |
WO2022255284A1 (ja) | 妊婦用経口投与剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07744713 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12281485 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008520585 Country of ref document: JP Ref document number: 200780010697.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007744713 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |